{"doi":"10.1002/1873-3468.14463","title":"Heteromerization between <scp>α<sub>1B</sub></scp>‐adrenoceptor and chemokine (<scp>C‐C</scp> motif) receptor 2 biases <scp>α<sub>1B</sub></scp>‐adrenoceptor signaling: Implications for vascular function","abstract":"Previously, we reported that chemokine (C‐C motif) receptor 2 (CCR2) heteromerizes with α 1B ‐adrenoceptor (α 1B ‐AR) in leukocytes, through which α 1B ‐AR controls CCR2. Whether such heteromers are expressed in human vascular smooth muscle cells (hVSMCs) is unknown. Bioluminescence resonance energy transfer confirmed formation of recombinant CCR2:α 1b ‐AR heteromers. Proximity ligation assays detected CCR2:α 1B ‐AR heteromers in hVSMCs and human mesenteric arteries. CCR2:α 1B ‐AR heteromerization per se enhanced α 1B ‐AR‐mediated Gα q ‐coupling. Chemokine (C‐C motif) ligand 2 (CCL2) binding to CCR2 inhibited Gα q activation via α 1B ‐AR, cross‐recruited β‐arrestin to and induced internalization of α 1B ‐AR in recombinant systems and in hVSMCs. Our findings suggest that CCR2 within CCR2:α 1B ‐AR heteromers biases α 1B ‐AR signaling and provide a mechanism for previous observations suggesting a role for CCL2/CCR2 in the regulation of cardiovascular function.","journal":"FEBS Letters","year":2022,"id":282550,"datarank":0.3226118429284347,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.01069561167645929,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.01069561167645929,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":1,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9589,"is_data_producer":true,"deposit_databanks":{"RefSeq":["AAB57792"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":442010,"name":"Anthony J. DeSantis","orcid":"0000-0002-0746-8605","position":1,"is_corresponding":false},{"id":442009,"name":"Garrett Enten","orcid":"0000-0002-9012-0246","position":2,"is_corresponding":false},{"id":959024,"name":"McWayne Weche","orcid":null,"position":3,"is_corresponding":false},{"id":804450,"name":"Jorge Marcet","orcid":"0000-0003-3728-8741","position":4,"is_corresponding":false},{"id":442011,"name":"Matthias Majetschak","orcid":"0000-0002-4086-0887","position":5,"is_corresponding":false},{"id":442008,"name":"Xianlong Gao","orcid":"0000-0003-3010-6810","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T00:29:19.691592Z","pmid":"35920096","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}